Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Crizotinib Receives Positive CHMP Opinion for ROS1-Positive NSCLC

July 25th 2016

The Committee for Medicinal Products for Human Use has adopted a positive option for crizotinib (Xalkori) as a treatment for adults with ROS1-positive advanced non–small cell lung cancer, suggesting an approval may be imminent.

Pennell Provides Perspective on EGFR-Targeted Agents in NSCLC

July 21st 2016

Nathan Pennell, MD, PhD, discusses 3 available—and competing—agents in EGFR-mutant non–small cell lung cancer, as well as ongoing clinical trials at Cleveland Clinic exploring other regimens for this patient population.

Dr. Wakelee on Immunotherapy Versus Targeted Agents in NSCLC

July 20th 2016

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses how immunotherapy agents compare with targeted therapies in patients with non–small cell lung cancer who harbor genetic alternations.

Kris Looks Ahead to Lung Cancer Care With Immunotherapy in Spotlight

July 20th 2016

Mark W. Kris, MD, discusses immunotherapy, frontline therapies for nonsquamous non–small cell lung cancer, and advancements in squamous cell carcinoma.

Immunotherapy/Chemo Combinations Show Potential in NSCLC

July 19th 2016

Shirish Gadgeel, MD, discusses the KEYNOTE-021 and KEYNOTE-189 studies, which are both examining pembrolizumab with chemotherapy in patients with non–small cell lung cancer.

Final Thoughts on NSCLC

July 19th 2016

What is on the Horizon for Immunotherapy in NSCLC?

July 19th 2016

Emerging Biomarkers for Lung Cancer

July 19th 2016

PD-L1 Biomarker Testing

July 19th 2016

Immunotherapy for Brain Metastases

July 19th 2016

Managing Toxicity in Immunotherapy for Lung Cancer

July 19th 2016

The Role of Immunotherapy in Metastatic NSCLC

July 19th 2016

Up-front Treatment Options for Squamous NSCLC

July 19th 2016

Progression in Non-Driver Adenocarcinoma

July 19th 2016

Treatment Approaches in Non-Driver Adenocarcinoma

July 19th 2016

ALK-Positive NSCLC

July 19th 2016

EGFR TKI Sequencing

July 19th 2016

Osimertinib for the T790M Resistance Mutation

July 19th 2016

TKIs for EGFR Del19 and Beyond Progression

July 19th 2016

Refining Use of EGFR TKIs, Adding Bevacizumab

July 19th 2016